doi:10.3389/fphar.2022.935823
Specify the names, doses, and duration of use
Thats where semaglutide drugs come in
[2] Additionally, GLP-1 agonists have been shown to reduce markers of systemic inflammation, including C-reactive protein (CRP), in patients with type 2 diabetes and cardiovascular disease, though these reductions are often modest
Semaglutide (Wegovy, Ozempic and Rybelsus): risk of non-arteritic anterior ischemic optic neuropathy (NAION)
When used in conjunction with other GLP-1 based therapies like Cagrisema, this dual-action could potentiate greater advancements toward effective weight control as well as enhanced glycemic managementa substantial boon for individuals dealing with obesity or diabetes-related health issues